Literature DB >> 19043376

Feasibility of simultaneous measurement of bone formation and bone resorption markers to assess bone turnover rate in postmenopausal women: an EPOLOS study.

Jacek Łukaszkiewicz1, Elzbieta Karczmarewicz, Paweł Płudowski, Maciej Jaworski, Edward Czerwiński, Andrzej Lewiński, Ewa Marcinowska-Suchowierska, Andrzej Milewicz, Marek Spaczyński, Roman S Lorenc.   

Abstract

BACKGROUND: One of the most important risk factors for osteoporotic fractures in postmenopausal women is elevated bone turnover (EBT), occurring in 25-30% of this population. This study's aim was to find a correlation between bone resorption and bone formation markers to assess bone turnover rate and qualify an individual postmenopausal woman as a possible EBT subject. MATERIAL/
METHODS: Three hundred twenty postmenopausal women (> or = one year after the last menstruation, < or = 70 years old) were enrolled at seven clinical sites in this cross-sectional observational study conducted within the EPOLOS. The group was a random sample of the population. The study was performed in a referral center involved in the diagnosis and treatment of osteoporosis. The exclusion criteria included pregnancy, cancer, fracture in the last year, and overweight (> 100 kg). Bone mineral density (BMD) measurements of the lumbar spine, total hip, trochanter, and femoral neck regions were performed. Bone resorption and formation rates were evaluated by serum levels of C-terminal telopeptide of type I collagen (CTX) and osteocalcin (OC), respectively.
RESULTS: Using logistic regression to correlate the concentrations of CTX and OC it was possible not only to distinguish the EBT subgroup, but also to construct a simple nomogram for easy classification of individual patients as possible EBT subjects. EBT patients showed generally decreased BMD values and increased bone formation and resorption rates.
CONCLUSIONS: Evaluation of both CTX and OC levels enables a more proper indication for EBT. The proposed nomogram may assist in evaluating outcome from the two markers of bone turnover.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19043376

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  7 in total

1.  Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls.

Authors:  P Wanby; R Nobin; S-P Von; L Brudin; M Carlsson
Journal:  J Endocrinol Invest       Date:  2016-02-05       Impact factor: 4.256

2.  Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis.

Authors:  V B Kraus; B Burnett; J Coindreau; S Cottrell; D Eyre; M Gendreau; J Gardiner; P Garnero; J Hardin; Y Henrotin; D Heinegård; A Ko; L S Lohmander; G Matthews; J Menetski; R Moskowitz; S Persiani; A R Poole; J-C Rousseau; M Todman
Journal:  Osteoarthritis Cartilage       Date:  2011-03-23       Impact factor: 6.576

3.  Estimation of serum osteocalcin and telopeptide-C in postmenopausal osteoporotic females.

Authors:  M Lateef; M Baig; A Azhar
Journal:  Osteoporos Int       Date:  2009-07-14       Impact factor: 4.507

4.  The soy isoflavones for reducing bone loss (SIRBL) study: a 3-y randomized controlled trial in postmenopausal women.

Authors:  D Lee Alekel; Marta D Van Loan; Kenneth J Koehler; Laura N Hanson; Jeanne W Stewart; Kathy B Hanson; Mindy S Kurzer; C Theodore Peterson
Journal:  Am J Clin Nutr       Date:  2009-11-11       Impact factor: 7.045

5.  Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.

Authors:  Annalisa Panico; Gelsy Arianna Lupoli; Francesca Marciello; Roberta Lupoli; Marianna Cacciapuoti; Addolorata Martinelli; Luciana Granieri; Daniela Iacono; Giovanni Lupoli
Journal:  Med Sci Monit       Date:  2011-08

6.  Evaluation of the validity of treatment decisions based on surrogate country models before introduction of the Polish FRAX and recommendations in comparison to current practice.

Authors:  Wojciech M Glinkowski; Jerzy Narloch; Bożena Glinkowska; Małgorzata Bandura
Journal:  Arch Med Sci       Date:  2016-06-23       Impact factor: 3.318

7.  Bone Turnover Markers and Osteoprotegerin in Uncomplicated Pregnancy.

Authors:  Hanna Styczynska; Kinga Lis; Izabela Sobanska; Agnieszka Pater; Joanna Pollak; Aneta Mankowska
Journal:  EJIFCC       Date:  2009-01-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.